From Fortune:



Novo Nordisk A/S, the Danish pharmaceutical company, is planning to build a large manufacturing facility outside of Dublin to keep up with the increasing demand for its obesity drugs. The facility would create up to 1,100 jobs and cover 1.6 million square feet. The success of their drugs has made Novo Nordisk Europe’s most valuable listed company, but the demand has also put a strain on their manufacturing capacity. The investment is expected to exceed €2 billion and the facility is projected to be fully operational by 2026. If approved, the development will include various manufacturing and administrative buildings.



Original: Ozempic maker Novo Nordisk plans ‘mega manufacturing’